Midatech Pharma PLC Result of AGM (8146U)

TIDMMTPH

RNS Number : 8146U

Midatech Pharma PLC

31 July 2020

31 July 2020

Midatech Pharma PLC

("Midatech" or the "Company")

Result of 2020 Annual General Meeting

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that at its Annual General Meeting (AGM) held at 11.30am today, with the exception of resolutions 6 (disapplication of pre-emption rights) and 7 (authority to purchase own shares) which failed to carry, all other resolutions put to the meeting were duly passed by shareholders by way of a poll.

With respect to resolution 6, 365,845 votes were cast for and 976,164 votes were cast against, representing 0.9% and 2.5% of eligible votes respectively. With respect to resolution 7, 515,216 votes were cast for and 858,043 were cast against, representing 1.3% and 2.2% of eligible votes respectively.

The UK Placing, which was announced on 27 July 2020, is not affected by the outcome of the voting above on the basis that allotment of the Placing Shares and Broker Option Shares has been made pursuant to existing share authorities which the Directors were given at the Company's General Meeting held on 2 March 2020.

Unless otherwise stated, capitalised terms used in this announcement have the meanings given to them in the announcement of the UK Placing on 27 July 2020.

For more information, please contact:

 
 
   Midatech Pharma PLC 
 Stephen Stamp, CEO, CFO 
 Tel: [phone] 
 www.midatechpharma.com 
 
 Panmure Gordon (UK) Limited (Nominated Adviser and Joint 
  Broker) 
 Freddy Crossley, Emma Earl (Corporate Finance) 
 James Stearns (Corporate Broking) 
 Tel: [phone] 
 
 Turner Pope Investments (TPI) Limited (Joint Broker, Sole 
  Bookrunner) 
 Andrew Thacker (Corporate Broking) 
  Tel: [phone] 
 IFC Advisory Limited (Financial PR and UK Investor Relations) 
 Tim Metcalfe / Graham Herring 
 Tel: [phone] 
 Email: [e-mail] 
 
 Edison Group (US Investor Relations) 
  Megan Paul / Laine Yonker 
  Tel: [phone] 
  [e-mail]/ [e-mail] 
           About Midatech Pharma PLC 
            Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: 
            MTP) is an R&D company focused on 'Making Medicines Better' 
            by improving delivery of drugs in the body. The Company combines 
            existing medications with its proprietary and innovative drug 
            delivery technologies to provide compelling oncology and rare 
            disease products that have the potential to powerfully impact 
            the lives of patients undergoing treatment for life threatening 
            diseases. 
            The Company has developed three in-house technology platforms, 
            each with its own unique mechanism to improve delivery of 
            medications to sites of disease. All of the Company's technologies 
            have successfully entered human use in the clinic, providing 
            important validation of the potential for each platform: 
             *    Q-Sphera(TM) platform: a disruptive micro-technology 
                  used for sustained release to prolong and control the 
                  release of therapeutics over an extended period of 
                  time (from weeks to months). 
 
 
             *    MidaSolve(TM) platform: an innovative nanotechnology 
                  used to dissolve insoluble drugs so that they can be 
                  administered in liquid form directly and locally into 
                  tumours. 
 
 
             *    MidaCore(TM) platform: a leading edge nanotechnology 
                  used for targeting medications to sites of disease. 
 
 
 
            By improving bio-delivery and biodistribution of approved 
            existing molecules, Midatech's unique R&D has the potential 
            to make medicines better, lower technical risks, accelerate 
            regulatory approval and route to market, and provide newly 
            patentable products. The platform nature of the technologies 
            allows the potential to develop multiple drug assets rather 
            than being reliant on a limited number of programmes. 
            Midatech's technologies are supported by 36 patent families 
            including 120 granted patents and an additional 70 patent 
            applications. 
            Midatech's headquarters and R&D facility is in Cardiff, UK. 
            For more information please visit www.midatechpharma.com 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

RAGKKDBQNBKDOON

(END) Dow Jones Newswires

July 31, 2020 09:48 ET (13:48 GMT)